Alliance for Clinical Trials in Oncology - Recruiting 18 years or older. - Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
Roswell Park Cancer Institute - Recruiting 50 years or older. - Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer.
AstraZeneca - Recruiting 18 years or older. - A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A PHASE III, RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY +/-CHEMOTHERAPY IN PATIENTS WITH 1-3 POSITIVE NODES, HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE BREAST CANCER WITH RECURRENCE SCORE (RS) OF 25 OR LESS. RXPONDER: A CLINICAL TRIAL RX FOR POSITIVE NODE, ENDOCRINE RESPONSIVE BREAST CANCER.
Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older. - A Single-Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms.
Medivation, Inc. - Recruiting 18 years or older. - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal.
University of Arizona - Recruiting N/A or older. - A Pilot Study Of Estradiol Followed By Exemestane For Post-Menopausal Hormone Receptor Positive Metastatic Breast Cancer After Prior Failed Endocrine Therapy: Reversing Endocrine Resistance.
Korean Breast Cancer Study Group - Recruiting N/A or older. - Assessment of Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women With Hormone Receptor Positive Breast Cancer.
Fudan University - Recruiting 18 years or older. - A Randomized ,Open Label Study Comparing the Efficacy of Zoladexr Combined With Arimidexr for 3-2 Years After Selective Estrogen Receptor Modulators (SERMs) as an Adjuvant Therapy for 2-3 Years Versus Continuing Tamoxifen up to 5 Years for Premenopausal Early Breast Cancer Patients With Hormone Receptor Positive, Lymph Node Positive or Tumorò 4cm..